Among the hundreds of genetic variants studied for thyroid disease, rs965513 at chromosome 9q22.33 stands alone as the strongest common-variant association with thyroid cancer risk ever identified¹¹ strongest common-variant association with thyroid cancer risk ever identified
Gudmundsson et al. Nature Genetics 2009; OR 1.75, P=1.7x10^-27. But this variant does more than influence cancer: it also shifts thyroid hormone levels in the general population, lowering TSH and T4 while raising T3. The locus sits within PTCSC2²² PTCSC2
Papillary Thyroid Cancer Susceptibility Candidate 2, a long noncoding RNA gene whose transcripts are downregulated in thyroid tumors, a long noncoding RNA gene, approximately 57 kb upstream of FOXE1³³ FOXE1
Forkhead Box E1, also known as thyroid transcription factor 2 (TTF-2), essential for thyroid gland development and differentiation — a transcription factor indispensable for thyroid gland formation during embryonic development.

The Mechanism

FOXE1 (also called TTF-2) is one of a small number of transcription factors that orchestrate thyroid organogenesis. FOXE1 knockout mice lack a thyroid gland entirely⁴⁴ FOXE1 knockout mice lack a thyroid gland entirely
Demonstrating the gene's essential role in thyroid morphogenesis and develop severe hypothyroidism. In adults, FOXE1 maintains the differentiated state of thyroid follicular cells.

The rs965513 variant resides within an intron of the PTCSC2 lncRNA gene, in a linkage disequilibrium block containing multiple enhancer elements⁵⁵ linkage disequilibrium block containing multiple enhancer elements
He et al. PNAS 2015 identified at least three regulatory elements overlapping the FOXE1 promoter that regulate FOXE1 expression. The risk A allele is associated with reduced expression of three genes simultaneously⁶⁶ reduced expression of three genes simultaneously
PTCSC2 (P=0.036), FOXE1 (P=0.012), and TSHR (P=0.024) in unaffected thyroid tissue: PTCSC2, FOXE1, and — notably — TSHR (the TSH receptor). The molecular mechanism involves MYH9 (myosin-9) binding to PTCSC2⁷⁷ MYH9 (myosin-9) binding to PTCSC2
He et al. PNAS 2017 showed MYH9 suppresses the bidirectional FOXE1/PTCSC2 promoter, while PTCSC2 reverses this inhibition at the shared bidirectional promoter of FOXE1 and PTCSC2. When PTCSC2 expression is reduced by the risk allele, MYH9-mediated suppression of FOXE1 goes unchecked, further reducing thyroid-protective gene activity.

The downstream consequence is twofold: reduced FOXE1 impairs thyroid cell differentiation and interferes with the p53 tumor suppressor pathway⁸⁸ interferes with the p53 tumor suppressor pathway
Affecting IGFBP3 and THBS1 expression in primary thyroid cells, while reduced TSHR expression alters thyroid sensitivity to TSH stimulation, explaining the variant's effects on circulating thyroid hormone levels.

The Evidence

The landmark Gudmundsson et al. 2009 GWAS⁹⁹ landmark Gudmundsson et al. 2009 GWAS
Gudmundsson et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nature Genetics 2009 identified rs965513 with an odds ratio of 1.75 for differentiated thyroid cancer (P=1.7x10^-27) in 192 Icelandic cases with replication in European cohorts. The same study found that each A allele was associated with a 5.9% decrease in TSH, a 1.2% increase in T3, and a 1.2% decrease in T4 in the general population.

A comprehensive meta-analysis of 23 studies¹⁰¹⁰ comprehensive meta-analysis of 23 studies
Wang et al. Oncotarget 2016, covering 20,736 cases and 142,400 controls across 13 countries confirmed the per-allele OR at 1.58 (95% CI 1.32-1.90), with Caucasians showing higher risk (OR 1.65) than Asians (OR 1.49). Under the recessive model, AA homozygotes had an OR of 2.10 (95% CI 1.66-2.64) compared to G-allele carriers, and under the homozygous model, AA vs GG showed an OR of 2.80 (95% CI 2.12-3.69).

A European cohort study of 277 cases and 309 controls¹¹¹¹ European cohort study of 277 cases and 309 controls
Penna-Martinez et al. Endocrine Oncology 2021 replicated the finding with a per-allele OR of 1.61 (95% CI 1.27-2.04), showing a clear allele-dosage effect: heterozygotes had OR 1.66 and AA homozygotes had OR 2.93 compared to GG.

The variant was also identified as a major genetic determinant for radiation-related thyroid cancer¹²¹² major genetic determinant for radiation-related thyroid cancer
Takahashi et al. found OR 1.65 for radiation-associated papillary thyroid cancer in Chernobyl survivors in Chernobyl survivors, suggesting that genetic background at this locus modifies radiation-induced thyroid cancer risk.

Regarding thyroid function in the general population, large GWAS studies have confirmed rs965513 as a significant locus for both TSH and free T4 levels. Individuals with the AA genotype have measurably lower TSH than GG carriers, consistent with reduced TSHR expression shifting the thyroid set point.

Practical Implications

The actionability of this variant differs depending on context. For thyroid cancer risk, the absolute risk increase is modest — thyroid cancer is relatively uncommon (annual incidence ~14 per 100,000), so even a 2-3 fold relative increase in AA carriers translates to a small absolute risk. However, in individuals with other risk factors — family history of thyroid cancer, history of radiation exposure, or thyroid nodules on imaging — this genotype can inform surveillance decisions.

For thyroid function, the variant's effect on TSH set point means that A-allele carriers may have naturally lower TSH levels. This is important context when interpreting thyroid function tests: a TSH in the low-normal range may be constitutionally appropriate for these individuals rather than a sign of subclinical hyperthyroidism.

Interactions

The rs965513 locus interacts with other thyroid-related variants through the shared regulatory architecture. The variant's simultaneous effect on FOXE1, PTCSC2, and TSHR expression means it influences both thyroid development/cancer pathways and thyroid hormone regulation. Individuals carrying both rs965513-AA and DIO2 rs225014-CC (Thr92Ala) may experience compound effects on thyroid function: reduced TSHR sensitivity from rs965513 combined with impaired T4-to-T3 conversion from DIO2 could create a more pronounced mismatch between standard thyroid function tests and tissue-level thyroid hormone activity. This interaction has not been formally studied but is biologically plausible given the converging pathways.

The Gudmundsson 2009 study found that individuals homozygous for both rs965513 and the 14q13.3 thyroid cancer variant had a 5.7-fold greater thyroid cancer risk compared to non-carriers at either locus, demonstrating multiplicative effects between thyroid susceptibility loci.

Five kilobases upstream of the interleukin-33 gene on chromosome 9, rs3939286 sits in the same regulatory neighbourhood as the well-characterised rs1342326 and rs992969 IL33 risk variants. IL-33¹¹ IL-33
An alarmin cytokine released from airway epithelial cells upon damage, allergen exposure, or viral infection; it binds the ST2 receptor (encoded by IL1RL1) on mast cells, ILC2 innate lymphoid cells, and eosinophils, triggering the type-2 inflammatory cascade that drives asthma, allergic rhinitis, and atopic disease is one of the pivotal upstream activators of atopic inflammation. rs3939286 lies in the regulatory landscape that controls how much IL-33 is produced in response to environmental insults — and the T allele is consistently associated with increased susceptibility to asthma, hay fever, nasal polyps, and chronic rhinosinusitis across independent study populations.

The Mechanism

rs3939286 at chr9:6,210,099 (GRCh38) occupies a chromatin-accessible region roughly 5 kb upstream of the IL33 transcription start site. The T allele (the GRCh38 reference allele at this position, but the population minor allele at ~25% European frequency) is embedded in a regulatory zone densely populated with GWAS signals for atopic disease. The mechanistic basis closely parallels the nearby rs992969 eQTL variant: upstream regulatory variants in this region modulate transcription factor binding and enhancer activity²² transcription factor binding and enhancer activity
Such as OCT-1/POU2F1 binding to an enhancer-blocking element, demonstrated for neighbouring IL33 GWAS variants in Aneas et al., Nat Commun 2021, ultimately controlling IL-33 mRNA output in bronchial epithelium. The C allele — the common protective form at ~75% European frequency — represents the baseline regulatory configuration. T allele carriers show an expression profile associated with elevated IL-33 availability during allergen or viral challenge, amplifying the alarmin signal through the ST2 → ILC2 → eosinophil type-2 axis.

Because rs3939286 and rs1342326/rs992969 tag the same upstream regulatory domain but at distinct positions, they may represent partially independent regulatory effects that compound in carriers of multiple IL33 risk alleles across this locus.

The Evidence

The first published association³³ first published association
Buysschaert et al. Allergy 2010; two-stage Belgian study; 284 nasal polyp patients and 427 controls across four hospitals identified rs3939286 as a susceptibility factor for nasal polyposis: the T allele (reported as "A-allele" on the older minus-strand convention) conferred OR 1.60 (95% CI 1.16–2.22) per allele in stage 1 and a combined OR of 1.53 (95% CI 1.21–1.96, p=0.00041). Combined risk assessment with the IL1RL1 variant rs1420101 further elevated nasal polyp risk, indicating that the full IL33/ST2 signalling axis contributes to NP pathogenesis.

In an Iranian asthma cohort (Matloubi et al. 2020⁴⁴ (Matloubi et al. 2020
126 asthmatics, 300 controls), homozygous T carriers showed OR 2.18 (95% CI 1.05–4.52) for asthma development, and the combined T/T + T/C genotype group showed OR 2.53 (95% CI 1.30–4.94) specifically for moderate and severe disease, suggesting a dose-response effect. The T allele preferentially associated with non-atopic and childhood-onset asthma subtypes in this study — a noteworthy contrast with some other IL33 variants, which lean toward atopic phenotypes.

The clearest evidence of a shared causal architecture comes from a Mendelian randomisation and colocalization study⁵⁵ Mendelian randomisation and colocalization study
Tu et al. Sci Rep 2024 demonstrating that asthma and chronic rhinosinusitis share the same causal genetic variant at this locus (posterior probability PP.H4 = 0.99) — effectively establishing rs3939286 as the colocalising signal linking IL-33 pathway activation to both upper and lower airway inflammatory disease.

The GWAS Catalog records large-scale phenome-wide associations for this variant at extraordinary significance levels: asthma at p=2×10⁻⁶⁶, hay fever at p=7×10⁻¹⁷, and nasal polyps at p=7×10⁻¹⁵, with the C allele (risk allele frequency ~0.75) showing protective beta coefficients in all three traits. These signals rank rs3939286 among the most robustly replicated IL33 locus variants in all of respiratory allergy genetics.

Practical Implications

T allele carriers — approximately 42% of Europeans carry at least one T (CT or TT) — face elevated risk across the atopic triad of asthma, allergic rhinitis, and nasal polyposis. The same IL-33 upstream regulatory mechanism that predisposes to these conditions also underlies susceptibility to chronic rhinosinusitis, creating a genetically coherent upper-lower airway disease trajectory. Monitoring biomarkers of IL-33/type-2 axis activity — fractional exhaled nitric oxide (FeNO) and peripheral blood eosinophil count — provides a quantitative readout of how active the downstream pathway is. Biologics targeting IL-33 (itepekimab) or the upstream alarmin cascade (tezepelumab, anti-TSLP) are mechanistically well-matched to this variant's pathophysiology when disease is moderate to severe and uncontrolled.

Interactions

rs3939286 shares its upstream regulatory territory with rs992969 (~400 bp upstream) and rs1342326 (~25 kb upstream) — both IL33 expression-associated GWAS variants. Carriers of multiple IL33 upstream risk alleles may face additive IL-33 expression burden, as each variant tags a distinct position in the regulatory domain controlling IL-33 output. The IL1RL1/ST2 receptor variant rs1420101 (T allele, reduced soluble ST2 decoy production) compounds with IL33 upstream risk alleles by simultaneously increasing IL-33 ligand availability and reducing IL-33 buffering via the decoy receptor — a compounding interaction along both arms of the IL-33/ST2 signalling axis.

DPYD encodes dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme¹¹ rate-limiting enzyme
DPD catabolizes 80-90% of administered 5-fluorouracil into inactive metabolites, preventing toxic accumulation in the bone marrow and gastrointestinal tract that breaks down fluoropyrimidine chemotherapy drugs. rs56038477 is a synonymous variant in exon 11 of DPYD (c.1236G>A, p.Glu412=) that, on its own, has no effect on DPD enzyme activity — it changes the DNA sequence but not the protein. Despite this, it is one of the most clinically important DPYD variants because it serves as the standard tag SNP²² tag SNP
A nearby variant in linkage disequilibrium with a functional variant, used as a cheap, easily-genotyped proxy when the true causal variant is harder to detect for the DPYD HapB3 haplotype, whose functional driver is the deep intronic splice variant c.1129-5923C>G (rs75017182).

The Mechanism — Why a Silent Variant Matters

c.1236G>A substitutes a glutamic-acid-coding codon (GAG) with another glutamic-acid-coding codon (GAA) at position 412 of the DPD protein. Because both codons specify glutamic acid (Glu, E), the substitution is synonymous — the resulting DPD enzyme is structurally and functionally identical to the wild-type protein. Synonymous variants typically have no clinical impact (occasional exceptions involve codon usage or mRNA stability effects, neither of which applies here for DPD).

What makes rs56038477 clinically important is its linkage disequilibrium³³ linkage disequilibrium
Two variants are in LD when they co-occur on the same chromosome more often than expected by chance, usually because they arose on the same ancestral haplotype and haven't been separated by recombination with rs75017182, the deep intronic c.1129-5923C>G variant that actually causes decreased DPD activity. The two variants sit within a few kilobases of each other in DPYD's intron-10/exon-11 region and arose together on a single European ancestral haplotype, travelling together ever since. When van Kuilenburg et al. characterised the HapB3 haplotype in 2010⁴⁴ van Kuilenburg et al. characterised the HapB3 haplotype in 2010
Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene. Hum Genet 2010;128(5):529-38, they found that every HapB3 patient carried both variants on the same chromosome, and functional studies isolated the splicing defect to the intronic variant alone.

This matters because the intronic c.1129-5923C>G is technically harder to genotype⁵⁵ technically harder to genotype
Deep intronic positions are rarely included on consumer SNP arrays and are sometimes not called reliably by short-read sequencing pipelines that don't target them explicitly; the exonic c.1236G>A is covered by virtually all clinical and consumer genotyping platforms than the exonic c.1236G>A, which falls in a well-covered coding region and is included on virtually all clinical pharmacogenomic panels and most consumer genotyping chips. For most of the 2010s, c.1236G>A was used as a cheap proxy for HapB3, and the clinical evidence base — including the CPIC guideline and the Alpe-DPD trial — was built on c.1236G>A genotyping as the HapB3 readout. CPIC continues to recommend it as the primary HapB3 tag in the 2018 guideline update.

Because DPYD sits on the minus strand of chromosome 1, the coding-strand G>A change that papers describe corresponds to a C>T change on the GRCh38 plus strand — which is how consumer genotyping chips and whole-genome sequencing files report it. The plus-strand reference allele at chr1:97573863 is C (the wild-type, non-HapB3 allele), and the T is the tag allele associated with HapB3.

The Evidence

rs56038477 has been used as the standard HapB3 tag SNP in the major clinical evidence supporting HapB3 screening:

• Amstutz et al. 2009 Pharmacogenomics⁶⁶ Amstutz et al. 2009 Pharmacogenomics
  The original DPYD haplotype assessment in 111 Swiss cancer patients, identifying HapB3 as one of several haplotypes significantly associated with severe 5-FU toxicity defined HapB3 as a multi-variant haplotype including c.1236G>A and identified it as a toxicity predictor.
• van Kuilenburg et al. 2010 Hum Genet⁷⁷ van Kuilenburg et al. 2010 Hum Genet
  Demonstrated complete co-occurrence of c.1236G>A and c.1129-5923C>G in HapB3 patients and identified the intronic variant as the functional driver via RT-PCR splicing studies confirmed the linkage and isolated the splicing mechanism to the intronic variant.
• Meulendijks et al. 2015 Lancet Oncol⁸⁸ Meulendijks et al. 2015 Lancet Oncol
  Individual patient data meta-analysis of 7,365 cancer patients across eight studies, genotyping HapB3 via c.1236G>A found that HapB3 carriers (c.1236G>A heterozygotes) had a 1.59-fold relative risk of severe fluoropyrimidine toxicity (95% CI 1.29-1.97, p<0.0001), independent of DPYD*2A and c.2846A>T effects.
• The CPIC 2018 guideline update⁹⁹ The CPIC 2018 guideline update
  Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther 2018 classified HapB3 as a decreased-function allele (activity score 0.5) and recommended 50% dose reduction, using c.1236G>A as the primary HapB3 tag.
• The Alpe-DPD prospective trial by Henricks et al.¹⁰¹⁰ The Alpe-DPD prospective trial by Henricks et al.
  1,103-patient Dutch multicentre trial prospectively genotyping for all four CPIC DPYD variants before fluoropyrimidine chemotherapy and applying 50% dose reductions to carriers implemented HapB3 screening via c.1236G>A genotyping and demonstrated that 50% dose reduction prevents severe toxicity without compromising overall or progression-free survival.
• European implementation cohorts such as PhotoDPYD 2023¹¹¹¹ PhotoDPYD 2023
  Spanish nationwide screen of 8,054 cancer patients using the four-variant CPIC panel including c.1236G>A as HapB3 proxy confirmed HapB3 allele frequencies of 2-4% in Spanish/European populations, consistent with gnomAD v4.

The Linkage Caveat — Why rs75017182 Should Be Genotyped Directly When Possible

Until 2024, the assumption was that c.1236G>A and c.1129-5923C>G were in complete linkage disequilibrium — every HapB3 carrier had both variants, and genotyping one was equivalent to genotyping the other. A 2024 paper by Turner and colleagues¹²¹² Turner and colleagues
Turner AJ, Derezinski AD, Gaedigk A, et al. Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing. Clin Transl Sci 2024;17(1):e13699 used large-scale population genomics data to show that the LD is very high but not perfect. A small number of individuals carry c.1236G>A (rs56038477) without the causal c.1129-5923C>G (rs75017182) splice variant — these individuals are functionally normal at the HapB3 locus and would be misclassified as high-risk by c.1236G>A genotyping alone. The reverse also occurs, though more rarely: isolated rs75017182 carriers without the c.1236G>A tag exist and would be missed by tag-only genotyping, putting them at risk of severe toxicity if treated at standard doses.

The clinical implication is that rs75017182 itself should be directly genotyped for HapB3 classification whenever possible, rather than relying on c.1236G>A alone. CPIC has not yet updated the guideline to reflect Turner 2024, and the existing prospective evidence (Alpe-DPD, Meulendijks) was built on c.1236G>A screening — so for now, a c.1236G>A positive result remains clinically actionable as a HapB3 indicator, but the field is moving toward direct splice-variant genotyping as the gold standard. GeneOps stores and interprets both variants separately for this reason: a user with rs56038477 (c.1236G>A) but NOT rs75017182 (the causal splice variant) is classified as functionally normal at the HapB3 locus, while a user with both variants is classified as a true HapB3 carrier requiring dose reduction. A compound action at the supervisor level handles the two-variant HapB3 diagnosis.

Practical Implications

If you carry one or two copies of the c.1236G>A variant (rs56038477), the clinical interpretation depends on whether you also carry the causal c.1129-5923C>G splice variant (rs75017182):

• c.1236G>A positive AND c.1129-5923C>G positive (true HapB3 carrier) — 50% initial fluoropyrimidine dose reduction per CPIC, managed identically to HapB3 heterozygotes via the rs75017182 pathway.
• c.1236G>A positive AND c.1129-5923C>G negative (tag-only carrier, per Turner 2024) — functionally normal DPD activity at the HapB3 locus; standard fluoropyrimidine dosing is appropriate at this locus. Other DPYD variants (*2A, *13, c.2846A>T) must still be ruled out separately.
• c.1236G>A positive with unknown c.1129-5923C>G status — treat as presumptive HapB3 carrier and apply 50% dose reduction. The splice variant carrier rate is very high in c.1236G>A positives (>95% LD in Europeans), and the conservative assumption is safer for a cancer patient. Request c.1129-5923C>G genotyping if your lab supports it.

In practice, most pharmacogenomic panels test c.1236G>A as the HapB3 readout, so most users will arrive at GeneOps with only the tag SNP genotyped. The GeneOps pipeline handles this by applying the conservative CPIC interpretation — c.1236G>A carrier = HapB3 presumed positive = 50% dose reduction recommended — unless the user also has a negative rs75017182 result available, in which case the tag-only status is reported with appropriate caveats.

Interactions

rs56038477 interacts directly with rs75017182, the causal splice variant of the HapB3 haplotype. A user carrying both variants (in cis on the same chromosome, which is the overwhelming majority case in European populations) is a true HapB3 carrier and should be managed as a decreased-function DPD metaboliser: 50% initial fluoropyrimidine dose reduction, therapeutic drug monitoring, cautious escalation to 65-85% of standard by cycle 3 if tolerated. The supervisor-level compound action for HapB3 encodes this combined genotype logic — it fires when both rs75017182 and rs56038477 are present and recommends the CPIC-level HapB3 management.

HapB3 also interacts with the other three CPIC-priority DPYD variants via the activity score system¹³¹³ activity score system
Activity score 2.0 = normal metaboliser; 1.0-1.5 = intermediate metaboliser (heterozygous for a no-function or decreased-function allele); 0-0.5 = poor metaboliser. A compound heterozygote carrying HapB3 alongside a no-function allele (DPYD*2A/rs3918290 or DPYD*13/rs55886062) drops to activity score 0.5 and is typically treated with fluoropyrimidine avoidance rather than dose reduction. A HapB3 + c.2846A>T (rs67376798) compound heterozygote scores 1.0 and requires more aggressive dose reduction than HapB3 alone.

First-degree relatives of c.1236G>A carriers have a ~50% prior probability of carrying the same variant and, because of the high linkage with the causal splice variant, a similar probability of being true HapB3 carriers. Cascade DPYD panel testing is appropriate for first-degree relatives who ever face fluoropyrimidine-based cancer treatment.

Brain-derived neurotrophic factor¹¹ Brain-derived neurotrophic factor
BDNF is the most abundant neurotrophin in the adult brain. It belongs to the nerve growth factor family and signals through the TrkB receptor to promote neuronal survival, differentiation, and synaptic plasticity (BDNF) is the brain's master growth signal for neurons. It drives the formation of new synaptic connections, strengthens existing ones, and supports neuronal survival across the lifespan. The Val66Met variant (rs6265) is the most studied polymorphism in all of neurogenetics — a single amino acid change that alters how BDNF is released from neurons, with measurable consequences for memory, brain structure, stress resilience, and response to exercise.

The Mechanism

BDNF exists in two secretory pools inside neurons. The constitutive pathway²² constitutive pathway
A steady, low-level release of BDNF that occurs regardless of neuronal activity, maintaining baseline trophic support provides a steady trickle of BDNF. The regulated pathway³³ regulated pathway
Activity-dependent release triggered by neuronal firing, essential for long-term potentiation (LTP) and memory consolidation. This is the pathway impaired by the Met allele releases BDNF in bursts when neurons fire — and this activity-dependent release is what drives long-term potentiation⁴⁴ long-term potentiation
LTP: the molecular basis of learning and memory. When neurons fire together repeatedly, their connections strengthen. BDNF is a key mediator of this process, memory consolidation, and synaptic remodeling.

The Val66Met substitution occurs in the prodomain⁵⁵ prodomain
The "pro" region of the BDNF precursor protein (pro-BDNF), which is cleaved before secretion. The prodomain contains the sorting signal that directs BDNF to secretory granules of the BDNF precursor. The methionine substitution disrupts a critical sorting signal⁶⁶ methionine substitution disrupts a critical sorting signal
Chen ZY et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci, 2004 that directs pro-BDNF into secretory granules. Met-BDNF is not properly sorted into these granules, so it cannot be released in the activity-dependent bursts that neurons need for plasticity. Total BDNF production is normal — but the regulated release that matters for learning and memory is impaired by roughly 18-30% in heterozygotes and more substantially in Met/Met homozygotes.

The Evidence

The landmark 2003 study by Egan and colleagues⁷⁷ landmark 2003 study by Egan and colleagues
Egan MF et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell, 2003 established the core finding: Met carriers showed reduced hippocampal activation during memory tasks and poorer episodic memory performance. This was confirmed by Hariri et al.⁸⁸ Hariri et al.
Hariri AR et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci, 2003, who found that the BDNF genotype-hippocampal interaction accounted for 25% of the variance in recognition memory.

A meta-analysis of 3,620 healthy subjects⁹⁹ meta-analysis of 3,620 healthy subjects
Molendijk ML et al. A systematic review and meta-analysis on the association between BDNF val66met and hippocampal volume. Am J Med Genet B Neuropsychiatr Genet, 2012 found Met carriers have modestly smaller hippocampal volumes (Cohen's d = 0.13, P = 0.02). The effect is real but small — and likely influenced by age, with some evidence that differences become more pronounced in older adults and in the context of neuropsychiatric illness.

The stress connection is equally important. The Met allele is associated with heightened HPA axis reactivity¹⁰¹⁰ heightened HPA axis reactivity
The hypothalamic-pituitary-adrenal axis is the body's central stress response system. Heightened HPA reactivity means a stronger cortisol response to stressors to psychological stress, and a meta-analysis of gene-environment interaction¹¹¹¹ meta-analysis of gene-environment interaction
Hosang GM et al. Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis. BMC Med, 2014 found that the Met allele significantly moderates the relationship between life stress and depression (P = 0.01 for stressful life events). A separate meta-analysis of Val66Met and depression¹²¹² meta-analysis of Val66Met and depression
Verhagen M et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder. Mol Psychiatry, 2010 found that in men specifically, the Met allele was associated with increased depression risk (OR 1.27, 95% CI 1.10-1.47).

Exercise — The Most Powerful BDNF Booster

Aerobic exercise is the strongest known stimulus for BDNF release. The Erickson et al. randomized controlled trial¹³¹³ Erickson et al. randomized controlled trial
Erickson KI et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA, 2011 demonstrated that one year of moderate aerobic walking increased hippocampal volume by 2% and significantly raised serum BDNF in 120 older adults — effectively reversing 1-2 years of age-related hippocampal shrinkage.

The relationship between Val66Met and exercise response is nuanced. A systematic review¹⁴¹⁴ systematic review
Liu T et al. The BDNF Val66Met polymorphism, regular exercise, and cognition: a systematic review. West J Nurs Res, 2020 found that exercise benefits cognition regardless of genotype, with Val/Val carriers showing greater exercise-associated memory benefits than Met carriers in several studies. The practical takeaway: regular aerobic exercise is beneficial for everyone, and may be especially important for Met carriers who start with reduced activity-dependent BDNF release.

Practical Implications

The Val66Met variant is not a disease-causing mutation. Roughly 36% of people worldwide carry at least one Met allele, and the majority function normally. The variant modestly shifts the curve on memory efficiency, stress resilience, and hippocampal integrity — effects that are most relevant when combined with aging, chronic stress, or sedentary lifestyle.

The actionable finding is clear: lifestyle factors that boost BDNF signaling — particularly aerobic exercise, quality sleep, and cortisol regulation — can compensate for reduced activity-dependent release. Met carriers who maintain consistent aerobic exercise may effectively normalize their BDNF signaling, while sedentary Met carriers are at greatest disadvantage.

Interactions

BDNF and COMT (rs4680)¹⁵¹⁵ COMT (rs4680)
Catechol-O-methyltransferase: the enzyme that breaks down dopamine in the prefrontal cortex. The Met158 variant (rs4680 AA) has lower enzyme activity, leading to higher dopamine levels both influence prefrontal cortex function through converging dopamine-BDNF pathways. A review of the molecular genetics of cognition¹⁶¹⁶ review of the molecular genetics of cognition
Savitz J et al. The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav, 2006 highlighted that BDNF promotes survival and function of dopaminergic neurons, while COMT determines dopamine clearance in prefrontal cortex. Carriers of both BDNF Met and COMT Met (rs4680 AA) may have a specific prefrontal vulnerability that benefits particularly from combined exercise and stress management strategies.

BDNF also interacts with the serotonin system. The Val66Met variant has been shown to interact epistatically with 5-HTTLPR¹⁷¹⁷ interact epistatically with 5-HTTLPR
Terracciano A et al. BDNF Val66Met is associated with introversion and interacts with 5-HTTLPR to influence neuroticism. Neuropsychopharmacology, 2010 to influence neuroticism and stress vulnerability, though 5-HTTLPR is a variable-length repeat rather than a single SNP.

The Val66Met variant may modulate response to antidepressant treatment. Met carriers show different response patterns to SSRIs depending on ethnicity, and the Met allele appears to impair the synaptogenic and antidepressant effects of ketamine¹⁸¹⁸ impair the synaptogenic and antidepressant effects of ketamine
Liu RJ et al. BDNF Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry, 2012 in preclinical models.

Glucose-6-phosphate dehydrogenase (G6PD) is a housekeeping enzyme that every cell carries, but it matters most in red blood cells — which have no mitochondria and therefore depend on G6PD as their sole source of NADPH¹¹ NADPH
Nicotinamide adenine dinucleotide phosphate (reduced form), a cellular reducing agent essential for regenerating glutathione and neutralizing oxidative stress. NADPH is the fuel that keeps the antioxidant defense of red blood cells running. When G6PD activity is significantly reduced, oxidative stress from drugs, infections, or certain foods overwhelms the red cell's defenses, causing the cell membrane to rupture — a process called acute hemolytic anemia²² acute hemolytic anemia
Sudden, triggered destruction of red blood cells causing jaundice, dark urine, fatigue, and anemia.

The rs76723693 G allele creates the G6PD Nefza variant, a missense change (c.968T>C) that substitutes leucine with proline at position 323 of the enzyme. Proline's rigid ring structure disrupts local protein folding, reducing enzyme stability and activity to approximately 50% of normal. This variant was first characterized in Tunisian patients³³ first characterized in Tunisian patients
Benmansour et al. 2013, Blood Cells Mol Dis; 293 G6PD-deficient individuals across familial and asymptomatic cases and is classified by the WHO as a Class III G6PD deficiency variant — mild to moderate, with residual activity in the 10–60% range. G6PD deficiency is the most common human enzymopathy, affecting more than 400 million people worldwide⁴⁴ affecting more than 400 million people worldwide, distributed across Africa, the Mediterranean, Middle East, and South and East Asia in patterns that mirror historic malaria endemicity — the G6PD-deficient red cell is less hospitable to Plasmodium parasites, conferring selective advantage in malaria-endemic regions.

The Mechanism

G6PD catalyzes the first step of the pentose phosphate pathway, converting glucose-6-phosphate to 6-phosphogluconate while reducing NADP⁺ to NADPH. In red blood cells, this NADPH is the only means of regenerating glutathione⁵⁵ glutathione
The cell's primary intracellular antioxidant; G6PD deficiency depletes reduced glutathione, leaving hemoglobin and the cell membrane vulnerable to oxidative damage. When NADPH falls below a critical threshold — triggered by oxidative challenge from drugs, fava bean ingestion (which liberates vicine and convicine, potent oxidants), or febrile infection — unprotected hemoglobin forms Heinz bodies⁶⁶ Heinz bodies
Precipitates of denatured hemoglobin that attach to the red cell membrane and accelerate its removal by the spleen and the cell is destroyed. The Leu323Pro substitution in G6PD Nefza reduces enzyme stability and substrate affinity for both glucose-6-phosphate and NADP⁺, confirmed in functional studies⁷⁷ confirmed in functional studies showing approximately 50% residual activity relative to the wild-type enzyme.

Because the G6PD gene is on the X chromosome, the variant is X-linked: males carrying the G allele are hemizygous and express the full deficiency phenotype. Females with one G allele are carriers and may have partial deficiency depending on X-chromosome inactivation patterns⁸⁸ X-chromosome inactivation patterns
Random silencing of one X chromosome in each female cell; if the wild-type allele is preferentially silenced (skewed inactivation), a heterozygous female can have enzyme activity as low as a hemizygous male.

The Evidence

The G6PD Nefza variant (c.968T>C) alone produces approximately 50% residual enzyme activity — biochemical analysis by Ramírez-Nava et al. 2017⁹⁹ biochemical analysis by Ramírez-Nava et al. 2017
Biochemical Analysis of Two Single Mutants that Give Rise to a Polymorphic G6PD A-Double Mutant. Int J Mol Sci, 2017 showed that Leu323Pro is the functionally dominant destabilizing mutation. This variant frequently co-occurs in cis with a second mutation, c.376A>G (p.Asn126Asp), forming the G6PD Betica-Selma complex allele with more severe enzyme dysfunction and pathogenic hemolytic anemia (ClinVar variation 1065168). The c.968T>C single variant is classified in ClinVar as Pathogenic/Likely pathogenic with 17/21 submissions in agreement.

An important and underappreciated clinical consequence of G6PD deficiency is its effect on HbA1c measurements. Because G6PD-deficient red cells have a shorter lifespan, hemoglobin has less time to become glycated, producing systematically lower HbA1c readings despite normal or elevated blood glucose levels¹⁰¹⁰ systematically lower HbA1c readings despite normal or elevated blood glucose levels
Nature Medicine 2024 found that G6PDdef carriers showed significantly higher glucose but lower HbA1c during the pre-diabetes period, and accounted for 12% of diabetic retinopathy and 9% of neuropathy cases in African ancestry participants of the ACCORD trial. This diagnostic gap means G6PD-deficient individuals can meet diabetes diagnostic thresholds by blood glucose criteria while appearing pre-diabetic by HbA1c — a clinically dangerous misclassification that delays treatment and intensification of therapy.

Practical Actions

The primary goal for G6PD Nefza carriers is avoiding oxidative triggers. The most evidence-supported prohibitions are seven drugs with solid evidence for hemolysis induction¹¹¹¹ seven drugs with solid evidence for hemolysis induction
Youngster et al. 2010, Drug Safety, evidence-based review of MEDLINE, PubMed, Cochrane: primaquine, dapsone, rasburicase, nitrofurantoin, methylene blue, phenazopyridine, and toluidine blue. Fava beans (broad beans, Vicia faba) and their pollen must also be avoided — the pyrimidine glycosides vicine and convicine undergo oxidative metabolism that overwhelms G6PD-deficient red cells. Hemolytic episodes triggered by infection are common and typically self-limiting, but severe episodes require urgent medical evaluation.

For diabetes screening and management, carriers should request fasting plasma glucose or a 2-hour oral glucose tolerance test (OGTT) rather than relying on HbA1c alone. If HbA1c is used, clinicians should apply a genotype-adjusted threshold — current evidence supports treating an HbA1c reading as representing meaningfully higher true glycemic exposure than the number suggests.

Interactions

The rs76723693 G allele can occur in cis with rs2230037 (G6PD c.376A>G, p.Asn126Asp), forming the G6PD Betica-Selma double mutant (ClinVar 1065168). This compound allele causes more severe enzyme deficiency and a higher risk of nonspherocytic hemolytic anemia than either mutation alone. Individuals who test positive for rs76723693 should ideally have both variants assessed to determine whether the compound allele is present.

The HbA1c interference from G6PD deficiency interacts critically with common diabetes screening pathways that rely exclusively on HbA1c — an important interaction with variants in the glycation and hemoglobin pathway. Concurrent hemoglobinopathies (e.g., sickle cell trait, thalassemia) further complicate HbA1c reliability and may compound the interpretation challenge.

Your NOS3 gene encodes endothelial nitric oxide synthase (eNOS), the enzyme that produces nitric oxide (NO)¹¹ nitric oxide (NO)
a gaseous signaling molecule that dilates blood vessels, prevents platelet aggregation, and protects the endothelium from inflammation and atherosclerosis. Without adequate NO, blood vessels stay more constricted and arterial stiffness rises in the cells lining your blood vessels. Among the many variants studied in this gene, rs891512 stands out for a specific reason: in a study genotyping 11 NOS3 polymorphisms across 726 participants from the MRC Ely Study, it was the only variant significantly associated with blood pressure²² only variant significantly associated with blood pressure
Vimaleswaran KS et al. Habitual energy expenditure modifies the association between NOS3 gene polymorphisms and blood pressure. Am J Hypertension, 2008 at rest. The association was strongest in physically active individuals, making rs891512 a clinically relevant gene-lifestyle interaction variant.

The Mechanism

rs891512 is located within intron 25 of NOS3 (IVS25+15 G>A) — 15 nucleotides into the intron after exon 25. On the GRCh38 reference genome the G allele is most common (~80% globally), while the A allele appears at roughly 20% in Europeans. Although intronic variants do not change the amino acid sequence, they can alter splicing factor binding³³ splicing factor binding
Splicing factors are proteins that direct how pre-mRNA introns are removed and exons joined together. Binding sites for these factors are concentrated near intron-exon junctions, and a variant that alters a binding site can cause aberrant splicing — including exon skipping or inclusion of intronic sequence — that disrupts the final protein. Bioinformatic analysis of rs891512 predicts that the A allele alters binding of the SF2/ASF splicing factor⁴⁴ SF2/ASF splicing factor
Serine/arginine-rich splicing factor 1 (SRSF1), a key regulator of constitutive and alternative splicing that binds exonic and intronic splicing enhancers, potentially causing defective splicing that yields a truncated or altered eNOS protein with lower enzymatic activity.

This mechanism aligns with what is known about NOS3 alternative splicing: truncated eNOS isoforms can form heterodimers with full-length enzyme and reduce overall NO output⁵⁵ NO output
Lorenz M et al. Alternative splicing in intron 13 of the human eNOS gene: a potential mechanism for regulating eNOS activity. FASEB J, 2007. The functional consequence is lower vascular NO bioavailability — the same downstream effect as the well-characterized Glu298Asp (rs1799983) coding variant, but through a different molecular route.

The Evidence

The most rigorous study of rs891512 comes from the MRC Ely Study of 726 adults⁶⁶ MRC Ely Study of 726 adults
Vimaleswaran KS et al. Habitual energy expenditure modifies the association between NOS3 gene polymorphisms and blood pressure. Am J Hypertension, 2008. Researchers genotyped 11 NOS3 polymorphisms and found that among all variants tested, only IVS25+15 (rs891512) was independently associated with resting blood pressure. GG homozygotes had diastolic BP 2.8 mmHg lower (P = 0.016) and systolic BP 1.9 mmHg lower (P = 0.018) than A-allele carriers. Crucially, this effect was amplified by physical activity: in the most active tertile, GG homozygotes showed BP reductions of 4.9 mmHg diastolic and 3.8 mmHg systolic compared to A-allele carriers — a compelling gene-lifestyle interaction.

Cardiovascular disease associations have been reported in a Tunisian cohort of 274 CAD cases and 162 controls⁷⁷ a Tunisian cohort of 274 CAD cases and 162 controls
Letaief Afef et al. Endothelial nitric oxide gene polymorphisms and their association with coronary artery disease in Tunisian population. Anatol J Cardiol, 2017. The A allele was significantly enriched in cases (28.8%) versus controls (16.9%), with an OR for CAD of 1.99 (95% CI 1.40–2.82; P < 0.001). The genotype distribution difference between cases (AA 11.4%, GA 34.7%, GG 53.9%) and controls (AA 2.5%, GA 29.7%, GG 67.8%) was also statistically significant (P = 0.006). A smaller Chilean study in type 2 diabetes patients⁸⁸ smaller Chilean study in type 2 diabetes patients
Seelenfreund D et al. Association of the intronic polymorphism rs891512 (G24943A) of the endothelial nitric oxide synthase gene with hypertension in Chilean type 2 diabetes patients. Diabetes Res Clin Pract, 2012 (n = 93 patients, 76 controls) found significant association of the A allele with hypertension (p < 0.05), with A-allele frequency of 15% in that population.

In exercise genetics, deep-targeted NOS3 sequencing found that after vigorous-intensity cycling (100% VO2 peak), the A allele explained 5.6–7.6% of the variance in post-exercise hypotension among African American participants (P < 0.001 for diastolic BP), with minor allele carriers showing a substantially larger post-exercise BP decrease than GG homozygotes. The effect was absent at moderate intensity (60% VO2 peak), indicating the interaction is exercise-intensity-specific.

Practical Implications

The core finding for A-allele carriers is that your resting blood pressure tends to run modestly higher than the GG genotype. The good news embedded in the data is that the genetic disadvantage shrinks substantially with physical activity — GG carriers who are active show the largest benefit, but the data also imply that A-allele carriers who are habitually active narrow the BP gap considerably. Vigorous aerobic exercise appears to be particularly important, as the gene-exercise interaction is strongest at high exercise intensity.

Dietary nitrate from beetroot and nitrate-rich vegetables offers an alternative NO production pathway that is independent of eNOS altogether — it proceeds via the entero-salivary nitrate-nitrite-NO pathway. For A-allele carriers with elevated BP or blunted eNOS function, regular consumption of high-nitrate vegetables or beetroot juice (400–500 mg nitrate) can measurably reduce blood pressure and improve endothelial function.

Interactions

rs891512 is located in the same gene as the well-characterized Glu298Asp variant (rs1799983)⁹⁹ Glu298Asp variant (rs1799983)
missense variant changing amino acid 298 from glutamic acid to aspartic acid, making eNOS more susceptible to proteolytic degradation and reducing NO output, which affects eNOS protein stability. The two variants are in incomplete linkage disequilibrium, meaning they provide partially additive information about NOS3 function. Carrying risk alleles at both positions could compound reduced NO production through distinct mechanisms — impaired splicing (rs891512) and accelerated protein degradation (rs1799983).

The rs891512 exercise-BP interaction also suggests synergy with the promoter variant rs2070744 (T-786C)¹⁰¹⁰ rs2070744 (T-786C)
a regulatory variant that reduces NOS3 gene expression by approximately 25%; the T allele is protective and the C allele reduces promoter activity and eNOS mRNA levels, which affects eNOS transcription level. Compound actions for NOS3 multi-variant combinations should be considered when a user carries risk alleles at rs891512 and rs1799983 or rs2070744 simultaneously.

Genome-wide association studies routinely identify non-coding variants as the top signals at causal loci. rs4129267 is a textbook case: an intronic variant in the IL-6 receptor gene (IL6R) on chromosome 1q21 that has no direct protein-changing effect, but is in perfect linkage disequilibrium (r²=1) with rs2228145, the missense variant that alters amino acid 358 from aspartate to alanine (Asp358Ala) and substantially changes how the IL-6 receptor is shed from cell surfaces. Carrying the T allele at rs4129267 is biologically equivalent to carrying the risk-associated 358Ala allele — every T-allele chromosome also carries 358Ala at rs2228145.

The Mechanism

IL-6 signals through two distinct modes: classical signaling¹¹ classical signaling
Classical IL-6 signaling requires membrane-bound IL-6Rα on the target cell. Only hepatocytes, monocytes, and certain lymphocytes express this receptor, making them the primary targets of classical IL-6 action: acute-phase protein production, CRP synthesis, and Th17 polarization via the cell-surface receptor, and trans-signaling²² trans-signaling
Trans-signaling uses the shed, soluble form of IL-6Rα (sIL-6Rα) to activate cells that lack membrane-bound receptor, including endothelial cells, smooth muscle cells, neurons, and Th2-permissive immune progenitors — dramatically broadening IL-6's reach via the shed soluble receptor. The Asp358Ala substitution tagged by rs4129267-T increases ectodomain shedding by the ADAM10 and ADAM17 metalloproteases. The net result per T allele: circulating sIL-6R rises by approximately 34.6%, membrane IL-6Rα density on CD4+ T cells and monocytes falls by up to 28%, classical signaling weakens, and trans-signaling strengthens. CRP and fibrinogen decrease; Th2-permissive responses increase.

The intronic position of rs4129267 means it has no direct functional role. It tags the Asp358Ala functional variant — its value as a marker arises entirely from its co-inheritance with rs2228145-C on the same chromosome.

The Evidence

The Ferreira et al. Lancet GWAS (2011)³³ Ferreira et al. Lancet GWAS (2011)
2,669 Australian asthmatics and 4,528 controls, combined with GABRIEL consortium and four in-silico replication cohorts; total n=57,800 identified rs4129267 as a genome-wide significant risk locus for asthma within IL6R (OR 1.09, combined p=2.4×10⁻⁸). This was the landmark study establishing IL6R as an asthma susceptibility gene and the study that first raised the possibility that IL-6 receptor antagonists (tocilizumab) might have therapeutic potential in a genotype-stratified asthma population.

Hawkins et al. (JACI, 2012)⁴⁴ Hawkins et al. (JACI, 2012)
Lung function study in asthmatic adults from the Severe Asthma Research Program (SARP) and Chicago Subcohort of the Chicago Asthma Genetics Study (CSGA); n=355 European-ancestry asthmatics confirmed that rs4129267 and rs2228145 are in perfect LD (r²=1), establishing that any genetic finding at one variant directly applies to the other. The 358Ala allele (tagged by rs4129267-T) associated with reduced FEV1, FVC, and FEV1/FVC ratio across both cohorts (combined p=0.003), and was enriched in severe asthma phenotypic clusters.

The Revez et al. study (Genes Immun, 2013)⁵⁵ Revez et al. study (Genes Immun, 2013)
16,705 asthmatics and 30,809 controls from the Australian Asthma Genetics Consortium and international replication cohorts used rs4129267 as the proxy SNP for the IL6R locus and demonstrated that each allele corresponds to approximately 20 ng/mL higher circulating sIL-6R, directly quantifying the biochemical shift associated with the tagging variant.

A cumulative evidence review across 155 IL6R studies and 80 polymorphisms (Zhang et al., Front Immunol, 2022⁶⁶ Zhang et al., Front Immunol, 2022
Systematic review covering 102 disease associations for IL6R variants) assigned rs4129267 strong-evidence associations with cardiovascular diseases and inflammatory diseases including asthma — the same disease spectrum as rs2228145, as expected from their r²=1 LD.

A notable pharmacological dimension emerged from Key et al. (J Cardiovasc Nurs, 2022)⁷⁷ Key et al. (J Cardiovasc Nurs, 2022)
Adults at cardiovascular risk; cross-sectional study examining inflammatory genotype × psychological stress interactions: rs4129267 genotype moderated the relationship between anxiety and circulating IL-6. The association between anxiety and elevated IL-6 was significant only in CC homozygotes (b=0.243, P<0.001), suggesting the IL6R haplotype shapes not only baseline IL-6 signaling but also IL-6 reactivity to psychosocial stressors.

Practical Actions

Because rs4129267 tags the Asp358Ala functional variant in perfect LD, all clinical implications of rs2228145 apply equally here. TT homozygotes carry two copies of the receptor-shedding haplotype: the same elevated sIL-6R, the same impaired classical signaling, the same reduced CRP, the same increased Th2 susceptibility, and the same highest asthma risk from the IL6R locus.

The cardiovascular paradox is also present: the T-allele haplotype that increases asthma risk simultaneously reduces coronary heart disease risk through impaired classical IL-6 signaling and lower CRP production. CC homozygotes have the highest classical IL-6 signaling activity and are more susceptible to CRP-mediated cardiovascular inflammation.

For CT heterozygotes: effects are intermediate. The allele count dose-response means one copy of the T haplotype partially shifts the IL-6 signaling balance — modest increase in asthma susceptibility, modest reduction in CHD risk, neither effect dominant in isolation.

Interactions

As a tag SNP in perfect LD (r²=1) with rs2228145 (Asp358Ala), rs4129267 and rs2228145 share all documented interactions. The most relevant IL6R haplotype partner on the platform is rs12133641, a deep intronic IL6R variant with partially overlapping cardiovascular-protective and atopic-risk associations. Carriers of risk alleles at both loci may show a more pronounced shift in the classical-versus-trans signaling balance than either variant predicts alone.

The IL6R locus interacts with upstream alarmins and cytokines that drive trans-signaling. IL-33 (rs992969), TSLP, and STAT6 variants that independently increase Th2 polarization can compound with the IL6R T-allele effect — individuals who carry risk alleles across multiple Th2-pathway variants experience additive atopic susceptibility beyond what the IL6R locus alone predicts.

Pain is not simply a signal your nerves generate — it is a sensation your brain calibrates continuously, amplifying or dampening incoming nociceptive input based on the availability of pain-modulating neuropeptides. The EIPR1 gene¹¹ EIPR1 gene
EARP complex and GARP complex interacting protein 1; also known by its original name TSSC1 (tumor-suppressing subtransferable candidate 1); located on chromosome 2p25.3 encodes a WD40-domain protein that sits at an unexpected point of control in this system: the sorting of neuropeptides into the dense-core vesicles that neurons use for regulated, stimulus-triggered release.

The Mechanism

EIPR1 acts as a molecular bridge between two endosomal trafficking complexes — EARP (endosome-associated recycling protein)²² EARP (endosome-associated recycling protein)
Retrieves membrane proteins from endosomes back to the plasma membrane and GARP (Golgi-associated retrograde protein), which returns cargo from endosomes to the trans-Golgi network. Together these complexes manage the endosomal sorting compartment, a staging area through which neuropeptide precursors pass on their way into mature dense-core vesicles (DCVs).

Dense-core vesicles³³ Dense-core vesicles
Large secretory organelles distinct from conventional synaptic vesicles; they package and release neuropeptides, biogenic amines, and peptide hormones including substance P, CGRP, enkephalins, and brain-derived neurotrophic factor are the primary vehicles for neuropeptide secretion throughout the nervous system. When EIPR1 function is impaired, cargo fails to sort correctly into maturing DCVs — it accumulates in the perinuclear region rather than being packaged and shipped to axonal terminals. Loss of EIPR1 in insulin-secreting cells reduces regulated secretion⁴⁴ Loss of EIPR1 in insulin-secreting cells reduces regulated secretion
Topalidou et al. 2020 and disrupts EARP localization on endosomal membranes.

In the brain, EIPR1 is expressed broadly, with highest levels in the basal ganglia, cerebral cortex, amygdala, and hypothalamus — regions central to both pain processing and descending pain modulation. The intronic rs58194899 variant likely modulates EIPR1 expression or splicing efficiency in a tissue-specific manner rather than altering the protein sequence directly. The A allele, which reduces pain sensitivity, may increase EIPR1 activity or expression in relevant neural circuits, improving neuropeptide packaging and thereby enhancing endogenous pain suppression.

The Evidence

Fontanillas et al. 2022⁵⁵ Fontanillas et al. 2022
23andMe GWAS; 25,321 participants scored on the Pain Sensitivity Questionnaire; cold pressor test arm (n=6,853) did not replicate this signal performed the largest genetic analysis of self-reported pain sensitivity to date. The rs58194899 A allele reached genome-wide significance (OR = 0.950, 95% CI 0.933–0.967, p = 1.9 × 10⁻⁸, MAF = 0.47) for lower PSQ scores, meaning each copy of the A allele is associated with approximately 5% lower odds of rating yourself as highly pain sensitive. The haplotype block spans 54 variants entirely within EIPR1's boundaries, implicating the gene specifically.

Importantly, the signal was not replicated in the cold pressor test (CPT) arm (p = 0.58), suggesting this variant influences subjective pain perception and central sensitization rather than peripheral nociceptive thresholds measured by acute cold pain tolerance.

Pathway enrichment analysis in the same study showed that PSQ-associated genes are overrepresented in neuronal development and glutamatergic synapse signaling pathways — consistent with a mechanism involving neuropeptide modulation of synaptic plasticity and central sensitization.

Recent clinical genetics work Ghosh et al. 2025⁶⁶ Ghosh et al. 2025
Eight individuals from six families with homozygous pathogenic EIPR1 variants; global developmental delays, corpus callosum underdevelopment, cerebellar atrophy confirms that severe EIPR1 loss of function produces a neurodevelopmental disorder with hallmark endolysosomal and dense-core vesicle defects — providing strong biological plausibility that common regulatory variation at this locus modifies neural function along a continuum.

The evidence level is rated emerging: the GWAS association is genome-wide significant and biologically coherent, but there is currently one discovery study without independent replication, and the functional mechanism (how exactly the intronic variant modulates EIPR1 in pain-relevant circuits) has not been characterized.

Practical Actions

This variant does not predict response to a specific drug class the way CYP2D6 or OPRM1 variants do. Instead, it shifts the baseline at which you perceive and report pain — a contextual factor that informs analgesic strategy and pain assessment.

For the GG genotype (higher pain sensitivity): standard pain scales may underestimate the need for analgesic coverage, particularly for perioperative and chronic pain. A proactive, multimodal approach — combining pharmacological and non-pharmacological pain management — is more likely to achieve adequate control than relying on reactive dose escalation.

For the AA genotype (lower pain sensitivity): standard doses of analgesics may provide sufficient effect, but there is also a risk of under-recognition of pain (your own and by providers) in conditions where pain is a key diagnostic signal.

Interactions

The pain sensitivity pathway involves multiple genetic modulators. OPRM1 rs1799971⁷⁷ OPRM1 rs1799971
Mu-opioid receptor A118G variant — G allele reduces receptor expression and opioid efficacy independently affects opioid analgesic response. Individuals carrying both high-sensitivity EIPR1 GG and OPRM1 G alleles face a double challenge: heightened pain experience combined with reduced opioid effectiveness. The COMT rs4680⁸⁸ COMT rs4680
Catechol-O-methyltransferase Val158Met — Met/Met associated with lower dopamine catabolism and higher pain sensitivity is another convergent pain sensitivity modifier worth considering when interpreting EIPR1 GG results. These interactions are not yet characterized in combined analyses and cannot support specific compound action recommendations, but awareness of co-occurring risk genotypes is clinically useful.

Presenilin-2 (PSEN2)¹¹ Presenilin-2 (PSEN2)
Encoded by the PSEN2 gene on chromosome 1q42.13; forms the catalytic aspartyl protease subunit of the gamma-secretase complex alongside presenilin-1, nicastrin, APH-1, and PEN-2 is one of three genes — alongside PSEN1 and APP — in which pathogenic mutations cause familial early-onset Alzheimer's disease (FAD). PSEN2 mutations are the rarest of the three causes (<5% of all early-onset familial cases) and are distinguished from their PSEN1 counterparts by later onset, broader age variability, and documented incomplete penetrance: not every carrier develops the disease.

The M239I mutation (c.717G>A; p.Met239Ile) substitutes methionine for isoleucine at position 239 of the mature PSEN2 protein. It was first described in 2000 in an Italian pedigree with autopsy-confirmed Alzheimer's disease and has subsequently been identified in multiple European families. The same methionine at position 239 is the site of the related M239V mutation (rs28936379), originally discovered in Volga German families in the original 1995 characterization of PSEN2 — making this codon a recognized hotspot for dominant pathogenic substitutions.

The Mechanism

Methionine 239 sits within transmembrane domain 5 of PSEN2, near the active site of the gamma-secretase complex²² gamma-secretase complex
The four-protein complex that cleaves type I transmembrane proteins within the lipid bilayer; its principal substrates relevant to Alzheimer's disease are the amyloid precursor protein (APP) and Notch. In normal APP processing, gamma-secretase cleaves APP to generate a mixture of Aβ peptides, predominantly the shorter Aβ40 form. The M239I substitution alters the geometry of the active-site pore, shifting the cleavage pattern toward production of the longer Aβ42 and Aβ43 peptides — forms that are far more prone to aggregation and amyloid plaque seeding. Published data from the AlzForum mutations database document that M239I produces decreased Aβ40/Aβ42 ratios and altered Aβ(37+38+40)/(42+43) ratios, consistent with this cleavage shift.

Beyond amyloid production, PSEN2 M239I disrupts calcium homeostasis in the endoplasmic reticulum (ER). Zatti et al. 2004³³ Zatti et al. 2004
Patient fibroblasts and engineered HEK293 cells expressing M239I showed significantly reduced Ca2+ release from ER stores compared to controls; capacitative calcium entry was unaffected, indicating specific impairment of store-filling rather than store-refilling. Neurobiol Dis. demonstrated that this ER calcium depletion is a direct consequence of the mutation. A follow-up study confirmed that M239I and related PSEN2 mutations reduce calcium content in both the ER and the Golgi apparatus⁴⁴ both the ER and the Golgi apparatus
This challenges the earlier "calcium overload" model of presenilin pathogenicity; instead, intracellular store depletion may impair neuronal signaling, energy metabolism, and protein processing in ways that promote neurodegeneration independently of amyloid.

Additionally, PSEN2 M239I alters trafficking of cystatin C — a neuroprotective secreted protein — in mouse primary neurons, reducing secretion of its glycosylated form and potentially diminishing the neuroprotective extracellular pool.

The Evidence

The clinical characterization comes primarily from two Italian research groups with access to the original and subsequent pedigrees. Finckh et al. 2000⁵⁵ Finckh et al. 2000
Neurology; Italian family with autopsy-confirmed AD; proband and affected relatives showed onset 44–58 years; two mutation carriers at ages 58 and 68 were cognitively unaffected at the time of examination, providing direct evidence of incomplete penetrance established the key clinical signature of this mutation: onset spanning the fifth and sixth decade, and a demonstrable rate of incomplete penetrance — in the family reported, 5 siblings carried the mutation, 3 developed AD and 2 did not.

A later case report by Testi et al. 2012⁶⁶ Testi et al. 2012
J Alzheimers Dis; characterized a PSEN2 M239I carrier with early frontal lobe hypoperfusion on SPECT imaging; clinical features included severe executive dysfunction, myoclonic tremor, and memory loss — confirming pathogenicity and illustrating the phenotypic heterogeneity, including potential atypical presentations extended the phenotypic picture, confirming the mutation's pathogenicity while documenting atypical presentations including early frontal involvement — a pattern not always seen in sporadic AD.

The key distinguishing feature from PSEN1 mutations is penetrance. PSEN1 mutations produce near-100% penetrance with onset reliably before age 60–65. PSEN2 mutations — including M239I — can skip generations or remain clinically silent past age 70 in some carriers. This creates genuine counseling uncertainty: a confirmed carrier faces substantial but not certain lifetime risk, and the age by which risk substantially accumulates spans four decades.

Practical Actions

For confirmed heterozygous carriers (AG genotype), the primary clinical needs are cognitive monitoring and genetic counseling for the family. Sporadic Alzheimer's prevention trials — including the A4 Study, AHEAD 3-45, and the DIAN-TU program — specifically seek to enroll pre-symptomatic carriers of high-penetrance FAD mutations including PSEN2 variants; enrollment provides access to experimental anti-amyloid interventions (lecanemab, donanemab) currently unavailable outside trials.

The monitoring goal is detecting cognitive change early — specifically mild cognitive impairment (MCI) — because cognitive reserve strategies and trial-based interventions are most effective in the pre-symptomatic or very early symptomatic window. Neurological review every 1–2 years, with neuropsychological testing covering episodic memory, executive function, and language, is appropriate for pre-symptomatic carriers in their 40s and beyond.

Interactions

The most clinically relevant interaction is with APOE genotype. While the Finckh 2000 paper specifically reported no influence of APOE genotype on phenotype in their family, this finding was based on a small pedigree and does not preclude population-level modulation. The APOE ε4 allele (rs429358) accelerates onset and increases severity in sporadic AD and in other FAD mutations; this interaction is plausible but not directly established for PSEN2 M239I specifically.

The homologous mutation at the same codon in PSEN1 — M233V (rs63751287) — produces a far more severe phenotype with onset in the mid-20s and near-100% penetrance, demonstrating how the same amino acid change in the two paralogue subunits of gamma-secretase produces profoundly different clinical trajectories.

The liver makes a continuous choice: phosphorylate incoming glucose (clearing it from the bloodstream) or conserve it. The enzyme doing the phosphorylating is glucokinase (GCK), and its gatekeeper is glucokinase regulatory protein (GKRP)¹¹ glucokinase regulatory protein (GKRP)
Encoded by the GCKR gene on chromosome 2; shuttles glucokinase in and out of the nucleus in response to fasting and fed-state signals, acting as the liver's primary brake on glucose uptake. rs780095 sits inside an intron of GCKR at a liver-specific enhancer element — a genomic switch that determines how much GKRP protein the liver produces.

This variant is mechanistically distinct from the better-characterized GCKR coding variant rs1260326 (P446L), which impairs GKRP's sensitivity to fructose-6-phosphate. rs780095 instead regulates GKRP protein abundance: the G allele sits on a three-SNP haplotype (rs780094-C / rs780095-G / rs780096-G) that drives higher GCKR expression and stronger FOXA2 transcription factor binding²² higher GCKR expression and stronger FOXA2 transcription factor binding
López Rodríguez et al. 2017 confirmed this in 132 heterozygous liver biopsy donors from the Kuopio Obesity Surgery cohort (KOBS); CGG haplotype showed higher H3K27Ac histone marks and FOXA2 binding relative to the TAC haplotype.

The Mechanism

FOXA2 is a hepatocyte-enriched transcription factor that coordinates fasting-state gene programs — including GKRP expression. The rs780095-G allele disrupts a MAFK transcription factor binding motif³³ MAFK transcription factor binding motif
MAF basic leucine zipper transcription factors regulate liver gene expression; rs780095 falls within a predicted MAFK binding site whose integrity differs between the G and A alleles within the intronic enhancer, shifting the regulatory balance toward stronger FOXA2-driven GCKR transcription. More GKRP protein in the hepatocyte means glucokinase spends more time sequestered in the nucleus and less time free in the cytoplasm phosphorylating glucose.

The downstream metabolic consequences follow directly: more GKRP inhibition → less hepatic glucose phosphorylation → slightly higher fasting glucose. Conversely, with glucokinase activity suppressed, less glucose enters the glycolytic pathway, less malonyl-CoA is generated, and hepatic de novo lipogenesis is partially braked. This produces a mirror image of the P446L trade-off: the G allele of rs780095 nudges fasting glucose upward while modestly protecting against GKRP-driven triglyceride overproduction — at least through the expression pathway.

The Evidence

The regulatory role of rs780095 was characterized in a 2017 Genome Medicine study⁴⁴ 2017 Genome Medicine study
López Rodríguez M, Kaminska D, Lappalainen K, Pihlajamäki J, Kaikkonen MU, Laakso M; Genome Medicine 9:63, 2017 using human liver biopsies from 132 individuals heterozygous for the rs780094-rs780095-rs780096 haplotype. In HepG2 hepatoma cells and primary mouse hepatocytes, the CGG haplotype (carrying rs780095-G) showed significantly greater FOXA2-induced transcriptional activity than the TAC haplotype. Allele-specific eQTL analysis in the human liver biopsies confirmed higher GCKR mRNA expression from the CGG haplotype allele.

At the metabolic phenotype level, the closely linked rs780094 and rs1260326 have been studied in tens of thousands of individuals. Orho-Melander et al. 2008⁵⁵ Orho-Melander et al. 2008
Fine-mapping study of the GCKR locus in >45,000 individuals across 12 independent cohorts; Nature Genetics 2008 established that the rs780094-T haplotype (TAC, which carries rs780095-A) is the TG-raising variant, associated with higher triglycerides (P=3×10⁻⁵⁶), lower fasting glucose (P=1×10⁻¹³), and elevated CRP (P=5×10⁻⁵). The ARIC Study (n=14,889)⁶⁶ ARIC Study (n=14,889)
Atherosclerosis Risk in Communities Study; prospective cardiovascular cohort quantified the per-allele effect at −1.93 mg/dl fasting glucose and +0.16 mmol/l triglycerides for the linked rs1260326-T allele.

A meta-analysis of gestational diabetes studies (1,122 women; 267 GDM cases)⁷⁷ meta-analysis of gestational diabetes studies (1,122 women; 267 GDM cases)
Jamalpour et al. 2018, Gene found that the rs780094-C allele (co-inherited with rs780095-G on the CGG haplotype) carries elevated GDM risk (OR 1.32, 95% CI 1.14–1.52), consistent with the glucose-raising effect of the high-GKRP-expression haplotype.

Practical Actions

The actionable interventions for the G allele centre on managing slightly elevated fasting glucose risk. Unlike the closely related rs1260326 P446L effect — where the triglyceride burden drives the main action items — the rs780095 G allele's primary concern is sustained mild elevation of hepatic glucose output through amplified GCK inhibition. Monitoring fasting glucose and HbA1c provides early detection, and dietary strategies that reduce hepatic glycolytic substrate (limiting refined carbohydrates at meals) directly address the elevated GKRP activity. Insulin sensitivity markers (fasting insulin, HOMA-IR) are also worth tracking because reduced hepatic glucose uptake can eventually contribute to compensatory hyperinsulinaemia.

Interactions

rs780095 is in a three-SNP haplotype with rs780094 and rs780096. The closely linked rs1260326 (P446L, r²=0.93 with rs780094) is the functional coding variant that drives the complementary TG-raising/glucose-lowering signal — individuals who carry the P446L T allele likely carry rs780095-A on the same haplotype and have a distinct metabolic profile (lower glucose, higher TG). The GCK promoter variant rs1799884 acts within the same hepatic glucose-sensing network; additive effects on fasting glucose have been reported for GCKR and GCK variants in combination. The PNPLA3 rs738409 G allele compounds hepatic fat risk for carriers of the TG-raising TAC haplotype (rs780095-A side), not the glucose-raising CGG haplotype side.